Vis enkel innførsel

dc.contributor.authorHalamoda-Kenzaoui, Blanka
dc.contributor.authorBaconnier, Simon
dc.contributor.authorBastogne, Thierry
dc.contributor.authorBazile, Didier
dc.contributor.authorBoisseau, Patrick
dc.contributor.authorBorchard, Gerrit
dc.contributor.authorBorgos, Sven Even F.
dc.contributor.authorCalzolai, Luigi
dc.contributor.authorCederbrant, Karin
dc.contributor.authorDi Felice, Gabriella
dc.contributor.authorDi Francesco, Tiziana
dc.contributor.authorDobrovolskaia, Marina A.
dc.contributor.authorGaspar, Rogério
dc.contributor.authorGracia, Belén
dc.contributor.authorHackley, Vincent A.
dc.contributor.authorLeyens, Lada
dc.contributor.authorLiptrott, Neill
dc.contributor.authorPark, Margriet
dc.contributor.authorPatri, Anil
dc.contributor.authorRoebben, Gert
dc.contributor.authorRoesslein, Matthias
dc.contributor.authorThürmer, René
dc.contributor.authorUrbán, Patricia
dc.contributor.authorZuang, Valérie
dc.contributor.authorBremer-Hoffmann, Susanne
dc.date.accessioned2020-11-24T12:47:09Z
dc.date.available2020-11-24T12:47:09Z
dc.date.created2019-06-18T09:27:18Z
dc.date.issued2019
dc.identifier.citationRegulatory toxicology and pharmacology. 2019, 106 187-196.en_US
dc.identifier.issn0273-2300
dc.identifier.urihttps://hdl.handle.net/11250/2689352
dc.description.abstractAn early dialogue between nanomedicine developers and regulatory authorities are of utmost importance to anticipate quality and safety requirements for these innovative health products. In order to stimulate interactions between the various communities involved in a translation of nanomedicines to clinical applications, the European Commission's Joint Research Centre hosted a workshop titled “Bridging communities in the field of Nanomedicine” in Ispra/Italy on the 27th −28th September 2017. Experts from regulatory bodies, research institutions and industry came together to discuss the next generation of nanomedicines and their needs to obtain regulatory approval. The workshop participants came up with recommendations highlighting methodological gaps that should be addressed in ongoing projects addressing the regulatory science of nanomedicines. In addition, individual opinions of experts relevant to progress of the regulatory science in the field of nanomedicine were summarised in the format of a surveyen_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.subjectimmune effectsen_US
dc.subjectcritical quality attributesen_US
dc.subjectregulatory scienceen_US
dc.subjectNanomedicineen_US
dc.titleBridging communities in the field of nanomedicineen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).en_US
dc.source.pagenumber187-196en_US
dc.source.volume106en_US
dc.source.journalRegulatory toxicology and pharmacologyen_US
dc.identifier.doi10.1016/j.yrtph.2019.04.011
dc.identifier.cristin1705513
dc.relation.projectEC/H2020/654190en_US
dc.relation.projectEC/H2020/761104en_US
cristin.unitcode7401,80,1,0
cristin.unitnameBioteknologi og nanomedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal